After a five-year pilot, only one company has successfully taken a test through parallel review, but there is growing industry interest.
The company hopes to simultaneously achieve premarket FDA approval and a national coverage determination from CMS for its NGS cancer panel.
Originally published April 23.
Originally published April 2.
Originally published Dec. 5.
By Turna Ray
This article has been updated to note that Exact Sciences has previously said it will submit the Cologuard test for parallel review by FDA and CMS. Originally published Oct. 7.
HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.
The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.
In Nature this week: glioma GWAS uncovers new risk loci, and more.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.